Arcturus Therapeutics Outlook Mixed, Targets Lowered

Arcturus Therapeutics Holdings Inc. faces a challenging investment outlook entering 2026. Citi lowered its price target to $7 while maintaining a neutral rating, reflecting caution in the SMID-cap biotech sector. In contrast, Roth Capital remains bullish with a $20 target and a buy recommendation, emphasizing the potential of its drug candidates. The company also showcased progress on its ARCT-810 therapy at the J.P. Morgan conference and now has access to significant financing flexibility via a $500 million equity issuance facility, providing key support for future development. These factors suggest a cautious wait-and-see phase for investors, balancing risks and opportunities around upcoming clinical milestones.